Ablation Catheter for Arrhythmia Cleared by FDA

An ablation catheter designed to eliminate short circuits in heart tissue that cause arrhythmia has been cleared by the U.S. Food and Drug Administration (FDA). Called Stinger, the catheter device is the product of Bard Electrophysiology (Lowell, MA, USA).

Ablation is accomplished by applying radiofrequency (RF) energy through the catheter directly to the tissue of the heart to destroy the circuits causing the heart to beat rapidly. Patients are usually discharged the same day or next day and can generally resume normal work and physical activity without restrictions. Bard says its catheter combines technology, comfort, and functionality to enhance controlled endocardial ablation.

"One of our primary goals at Bard Electrophysiology is to offer the electrophysiologist innovative, reliable products to address their complete clinical practice needs and continually improve outcomes,” said William H. Longfield, chairman and CEO.



Related Links:
Bard